We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04760743
Recruitment Status : Active, not recruiting
First Posted : February 18, 2021
Last Update Posted : May 10, 2022
Sponsor:
Information provided by (Responsible Party):
SK Bioscience Co., Ltd.

Brief Summary:
This study is to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.

Condition or disease Intervention/treatment Phase
COVID-19 (Healthy Volunteers) Biological: NBP2001 adjuvanted with alum (RBD 30μg/dose) Biological: NBP2001 adjuvanted with alum (RBD 50μg/dose) Other: Normal Saline Phase 1

Detailed Description:

This is a first-in-human, Phase I, randomized, placebo-controlled, observer-blinded study to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.

A total of 50 healthy adults between 19 and 55 years of age will be enrolled and block-randomized in a 4:1 ratio to receive 2 doses of either one NBP2001 formulation (Test group 1 or 2) or placebo saline (Placebo group).

Over the study period, participants will commonly attend 10 planned visits. Telephone calls will be made 7 days after each vaccination (Day 7+3 after Visit 2 and Visit 4). However, sentinel participants will be required to return at Day 7(+ 3 days) after 1st vaccination for rigorous safety assessment.

Study vaccination will comprise 2 intramuscular injections of saline placebo, or a 30 or 50μg dose of NBP2001 in an injection volume of approximately 0.5mL. The study vaccines will be injected preferably into the deltoid muscle of the upper arm at a 28-day interval.

Halting rules based on reactogenicity and safety outcomes are defined, and enrollment and study vaccination may be paused during the study if any halting rules are met.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years
Actual Study Start Date : December 17, 2020
Actual Primary Completion Date : April 2, 2021
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: low dose level cohort
2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 30μg/dose), 1 dose each on Day 0 and 28
Biological: NBP2001 adjuvanted with alum (RBD 30μg/dose)
Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.

Experimental: high dose level cohort
2 dose of NBP2001 adjuvanted with alum (Receptor Binding domain (RBD) 50μg/dose), 1 dose each on Day 0 and 28
Biological: NBP2001 adjuvanted with alum (RBD 50μg/dose)
Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.

Placebo Comparator: Placebo group
2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
Other: Normal Saline
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.




Primary Outcome Measures :
  1. Occurrence of immediate systemic reactions [ Time Frame: Through 30 minutes (2 hours for sentinel participants) post-vaccination ]
  2. Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination [ Time Frame: Through 7 days post-vaccination ]
  3. Occurrence of solicited systemic AEs during 7 days post each vaccination [ Time Frame: Through 7 days post-vaccination ]
  4. Occurrence of unsolicited AEs during 28 days post each vaccination [ Time Frame: Through 28 days post-vaccination ]
  5. Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period [ Time Frame: Through Day 0 to Day 365 post last vaccination ]
  6. GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA) [ Time Frame: Through Day 365 post last vaccination ]
  7. GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA [ Time Frame: Through Day 365 post last vaccination ]
  8. Percentage of participants with ≥ 4-fold rise from baseline in ELISA IgG titer [ Time Frame: Through Day 365 post last vaccination ]
  9. GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays [ Time Frame: Through Day 365 post last vaccination ]
  10. GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays [ Time Frame: Through Day 365 post last vaccination ]
  11. Percentage of participants with ≥ 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer [ Time Frame: Through Day 365 post last vaccination ]
  12. Cell-mediated response for both Th1 and Th2 (e.g. INF-γ, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system [ Time Frame: Through Day 28 post last vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Age

  1. Participant must be 19 to 55 years of age inclusive, at the time of signing the informed consent.

    Type of Participant and Disease Characteristics

  2. Participants who are healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and medical judgement of the investigator
  3. Participants who are able to attend all scheduled visits and comply with all study procedures.

    Weight

  4. Body mass index (BMI) within the range 18-30 kg/m2 at screening (inclusive)

    Sex and Contraceptive/Barrier Requirements

  5. Female participants of childbearing potential must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 21 days prior to the 1st study vaccination to 8 weeks after the last study vaccination
  6. Female participants with a negative urine or serum pregnancy test at screening

    Informed Consent

  7. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

Medical Conditions

  1. Any clinically significant respiratory symptoms (e.g. cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 72 hours prior to the 1st study vaccination. A prospective participant should not be included until 72 hours after the condition has resolved.
  2. History of virologically-confirmed COVID-19 disease, or definite or suspected exposure to anyone known to have SARS-CoV-2 infection
  3. History of virologically-confirmed SARS or MERS disease
  4. History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease
  5. Any positive test results for hepatitis B, C, or HIV at screening
  6. History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion
  7. History of hypersensitivity and severe allergic reaction (e.g. anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention
  8. History of malignancy within 5 years prior to the 1st study vaccination
  9. Significant chronic illness that, in the opinion of the investigator, might increase risk of severe COVID-19, or interfere with the evaluation of the study objectives (e.g. asthma, chronic pulmonary disease, cardiovascular disease, chronic liver disease, diabetes mellitus, uncontrolled hypertension, renal disorders)
  10. History of, or planned surgery under general anesthesia from 1 year prior to the 1st study vaccination through the study period
  11. Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g. neurologic or psychiatric conditions)
  12. Female participants who are pregnant or breastfeeding
  13. Current smokers or a recent smoking history within 12 weeks prior to the 1st study vaccination. Occasional smokers who smoke up to 10 cigarettes per month may be allowed to participate at the investigator's discretion

    Prior/Concomitant therapy

  14. Receipt of any medications or vaccinations intended to prevent COVID-19.
  15. Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine from enrollment through 28 days after the last study vaccination (Visit 7), except for influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
  16. Receipt of immunoglobulins and/or any blood or blood products within 12 weeks prior to the 1st study vaccination
  17. Chronic use (more than 2 consecutive weeks) of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (≥10mg prednisone/day or equivalent for more than 2 consecutive weeks) within 12 weeks prior to the 1st vaccination. The use of topical and nasal glucocorticoids will be permitted.

    Prior/Concurrent Clinical Study Experience

  18. Participation in another clinical study involving study intervention within 6 months prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during this study period.

    Other Exclusions

  19. Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.
  20. Healthcare worker or emergency response personnel in an occupation with a high risk of exposure to SARS-CoV-2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04760743


Locations
Layout table for location information
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam-si, Bundang, Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
SK Bioscience Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Myoung-Don Oh Seoul National University Hospital
Layout table for additonal information
Responsible Party: SK Bioscience Co., Ltd.
ClinicalTrials.gov Identifier: NCT04760743    
Other Study ID Numbers: NBP2001_001
First Posted: February 18, 2021    Key Record Dates
Last Update Posted: May 10, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Aluminum sulfate
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs